Showing results 1 to 1 of 1
Issue Date | Title | Journal Title |
---|---|---|
2022 | Preliminary interim data of elzovantinib (TPX-0022), a novel inhibitor of MET/SRC/CSF1R, in patients with advanced solid tumors harboring genetic alterations in MET: Update from the Phase 1 SHIELD-1 trial | EUROPEAN JOURNAL OF CANCER |